23andMe (NASDAQ:ME) Shares Down 5%

23andMe Holding Co. (NASDAQ:ME) shares traded down 5% on Friday . The company traded as low as 5.14 and last traded at 5.14. 83,528 shares traded hands during mid-day trading, a decline of 97% from the average session volume of 2,698,220 shares. The stock had previously closed at 5.41.

A number of equities research analysts recently weighed in on the company. Credit Suisse Group increased their price target on 23andMe from $13.00 to $14.00 and gave the company an “outperform” rating in a research note on Thursday, November 11th. Citigroup dropped their price target on 23andMe from $13.00 to $9.00 and set a “neutral” rating on the stock in a research note on Monday, December 20th.

The firm has a 50 day moving average of 8.32 and a two-hundred day moving average of 8.94.

23andMe (NASDAQ:ME) last announced its quarterly earnings results on Tuesday, November 9th. The company reported -0.04 EPS for the quarter, beating the Zacks’ consensus estimate of -0.13 by 0.09. The firm had revenue of 55.20 million for the quarter.

Institutional investors have recently bought and sold shares of the stock. Scotia Capital Inc. bought a new stake in 23andMe in the second quarter worth approximately $132,000. Monashee Investment Management LLC bought a new stake in 23andMe in the second quarter worth approximately $1,754,000. M&G Investment Management Ltd. bought a new stake in 23andMe in the third quarter worth approximately $1,218,000. Penserra Capital Management LLC bought a new stake in shares of 23andMe during the second quarter valued at approximately $196,000. Finally, Disruptive Technology Advisers LLC bought a new stake in shares of 23andMe during the second quarter valued at approximately $42,660,000. 12.84% of the stock is currently owned by institutional investors.

About 23andMe (NASDAQ:ME)

23andMe Holding Co operates as a consumer genetics and research company. The company provides a crowdsourced platform for genetic research. Its platform has generated various publications on the genetic underpinnings of a range of diseases, conditions, and traits, as well as enables it in pursuing drug discovery programs rooted in human genetics across various disease areas, including oncology, respiratory, and cardiovascular diseases, as well as other therapeutic areas.

Featured Article: Why does the United States have a lingering trade deficit?

Receive News & Ratings for 23andMe Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 23andMe and related companies with MarketBeat.com's FREE daily email newsletter.